替吉奥联合顺铂治疗晚期胃癌近期疗效观察

Effect observation of Tegafur combined with Lobaplatin in the treatment of patients with advanced gastric cancer

目的探讨替吉奥联合顺铂治疗晚期胃癌的近期疗效及安全性。方法将70例晚期胃癌患者随机分为观察组和对照组各35例,观察组给予替吉奥联合顺铂治疗,对照组给予5-氟尿嘧啶联合顺铂治疗。观察2组的近期疗效及不良反应情况,并进行对比、分析。结果观察组有效及临床收益率高于对照组;且血红蛋白减少及脱发Ⅲ～Ⅳ度发生率低于对照组,差异均有统计学意义(P<0.05)。结论替吉奥联合顺铂治疗晚期胃癌近期疗效好,不良反应少,是目前治疗晚期胃癌的一种较佳治疗方案,值得临床推广应用。

Objective To observe the efficacy and safety of chemotherapy combined Tegafur with Lobaplatin in ad- vanced gastric cancer patients. Methods 70 patients with advanced gastric cancer patients were randomly divided into obser- vation group and control group,each of 35 cases. The control group was treated with 5-fluorouracil and Lobaplatin. The treat- ment group was treated with Tegafur and Lobaplatin. The short-term efficacy and adverse reaction of 2 groups were observed and compared. Results The total effective rate and clinical benefit rate of the treatment group was much higher than that of control group; the incidence rate of main adverse reactions included bone marrow depression, nausea, vomiting and baldness the treat- ment group was lower than those of the control group, and the difference between 2 groups was statistically significant （ P 〈 0. 05）. Conclusion The chemotherapy combined Tegafur with Lobaplatin was effective and safe in treating patients with advanced gastric cancer,and the adverse events of which are tolerated. So it is worthy of clinical application.